A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of
belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in
patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in
ovarian and bladder cancer patients
The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer
patients. Enrollment of ovarian patients is complete.